After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.
The French drugmaker is reportedly thinking about including a CVR in its $9.3 billion bid for Medivation, but the move is unlikely to be enough to entice the target's shareholders.
Stocks with insider trader activity include DEPO, ARIA and ROG
Stocks with insider trader activity include RRD, KLIC and ROG
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.